3National Committee for Clinical Laboratory Standard, 2002. Performance standards for antimicrobial susceptibility testing. Wayne.Pennsylvania:NCCLS, 2002.1- 50.
4Jeijaszewicz J, Mlynarczyk G, Mlynarcqyk A. Antibiotic resistance in Gram-positive cocci. Int J Antimicrob Chemother, 2000,16:473-478.
5Mutnick AH, Biedenbach DJ, Turnidge JD, et al. Spectrum and potency evaluation of a new oxazolidinone, linezolid:report from the SENTRY Antimicrobial Surveillance Program, 1998-2000. Diagn Microbiol Infect Dis, 2002,43:65-73.
6Jones RN, Biedenbach DJ,Beach ML.Influence of patient age on the susceptibility patterns of Streptococcus pneumoniae isolates in North America (2000-2001):report from the SENTRY Antimicrobial Surveillance Program. Diag Microbiol Infect Dis, 2003,46:77-80.
7Biedenbach DJ, Stephen JM ,Jones RN. Antimicrobial susceptibility profile among β-haemolytic Streptococcus spp.collected in the SENTRY Antimicrobial Surveillance Program-North America, 2001. Diag Microbiol Infect Dis, 2003,46:291-294.
8Biedenbach DJ, Jones RN. Five-year analysis of Haemophilus influenzae isolates with reduced susceptibility to fluoroquinolones:prevalence results from the SENTRY Antimicrobial Surveillance Program. Diag Microbiol Infect Dis, 2003,46:55-61.
9Avanzini C, Bosio K, Volpe G, et al. Streptococcus pyogenes collected in Torino (northwest Italy) between 1983 and 1998:Survey of macrolide resistance and trend of genotype by RAPD. Microbial Drug Resistance, 2000,6:289-295.
10Mutnick AH, Biedenbach DJ, Jones RN. Geographic variations and trends in antimicrobial resistance among Enterococcus faecalis and Enterococcus faecium in the SENTRY Antimicrobial Surveillance Program (1997-2000). Diag Microbiol Infect Dis, 2003,46:63-68.
5Faria NA,Oliveira DC,Westh H,et al.Epidemiology of emerging methicillin-resistant Staphylococcus aureus (MRSA) in Denmark:A nationwide study with low prevalence of MRSA infection[J].J Clin Microbiol,2005,43(4):1836-1842.
6CLSI.Performance standards for antimicrobial susceptibility testing:16th informational supplement[S].Wayne,PA:Clinical and Laboratory Standards Institute,2006:M100-S16.
7Lowy FD.Antimicrobial resistance:the example of Staphylococcus aureus[J].J Clin Invest,2003,111(9):1265-1273.
8Gemmell CG,Edwards DI,Fraise AP,et al.Guidelines for the prophlaxis and treatment of methicillin-resis-tant Staphylococcus aureus(MRSA)infections in UK[J].J Antimicrob Chemother,2006,57(4):589.
9Anna M.Ferrara.Treatment of hospital-acquired pneu-monia caused by methicillin-resistant Staphylococcus aureus[J].Int J Antimicrob Agents,2007,30(1):19.
